Patient registration

World Leading Rehabilitation Expert Prof. Dr. Christopher Gutenbrunner Visits Siyi Intelligence

Retrieved on: 
Friday, August 18, 2023

Prof. Dr. Christopher Gutenbrunner said, " Therapists must teach patients how to use rehabilitation products correctly.

Key Points: 
  • Prof. Dr. Christopher Gutenbrunner said, " Therapists must teach patients how to use rehabilitation products correctly.
  • The feedback from patients will drive rehabilitation products iterate and update" while he was experiencing the rehabilitation products series for clinic and home.
  • At the recent Rehabilitation International Centennial Celebration Award Ceremony, Prof. Dr. Christopher Gutenbrunner appealed to respect human diversity, respect human rights, and promote equal participation and comprehensive development of disabilities.
  • Similarly, Siyi Intelligence always carries out the commitment to provide dignified rehab equipment for the disabled group.

Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

Retrieved on: 
Tuesday, August 8, 2023

ComboMATCH is a coordinated platform of clinical oncology trials sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health.

Key Points: 
  • ComboMATCH is a coordinated platform of clinical oncology trials sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health.
  • ComboMATCH includes a Patient Registration Trial led by ECOG-ACRIN, along with several treatment trials designed and led by the Alliance for Clinical Trials in Oncology, Children’s Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network.
  • To be selected for the trial, combinations must show evidence they may be more effective than single therapy in treating cancer.
  • Both the Myriad and Intermountain tests are now able to be used to identify patients that may be eligible for enrollment in a treatment study under ComboMATCH.

argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline

Retrieved on: 
Monday, January 9, 2023

argenx is planning for multi-dimensional expansion to reach more patients with VYVGART, its first-in-class neonatal Fc receptor blocker.

Key Points: 
  • argenx is planning for multi-dimensional expansion to reach more patients with VYVGART, its first-in-class neonatal Fc receptor blocker.
  • By the end of 2023, efgartigimod is expected to be approved, in regulatory review or in development in 13 severe autoimmune diseases.
  • argenx continues to invest in its discovery engine, the Immunology Innovation Program, to foster a robust innovation ecosystem and drive early-stage pipeline growth.
  • As of December 31, 2022, argenx had approximately $2.2 billion in cash, cash equivalents and current financial assets*.

Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Thursday, August 11, 2022

In the second quarter, we achieved major milestones in both of our clinical programs, said Bryan Stuart, Chief Executive Officer of Fulcrum Therapeutics.

Key Points: 
  • In the second quarter, we achieved major milestones in both of our clinical programs, said Bryan Stuart, Chief Executive Officer of Fulcrum Therapeutics.
  • Collaboration Revenue: Collaboration revenue was $1.9 million for the second quarter of 2022, as compared to $4.4 million for the second quarter of 2021.
  • G&A Expenses: G&A expenses were $11.1 million for the second quarter of 2022, as compared to $6.7 million for the second quarter of 2021.
  • ET to discuss its second quarter 2022 recent business highlights and financial results.

aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 10, 2021

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced third quarter 2021 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced third quarter 2021 results and provided a corporate update.
  • Reported positive results from a Phase 1b/2a multiple-ascending dose, placebo-controlled study of ATYR1923 in 37 patients with pulmonary sarcoidosis.
  • Based on the results of the study, the company expects to initiate a registrational trial in pulmonary sarcoidosis next year.
  • G&A Expenses: General and administrative expenses were $2.6 million for the third quarter of 2021.

The Tryten Healthcare Team Announces COVID Rapid Response Mobile Telehealth Carts for Timely Adaptive Care

Retrieved on: 
Thursday, October 14, 2021

Rapid response telehealth solutions help affected areas bring in virtual providers from areas not currently impacted, helping to free up the local providers for hands on care.

Key Points: 
  • Rapid response telehealth solutions help affected areas bring in virtual providers from areas not currently impacted, helping to free up the local providers for hands on care.
  • Mobile cart-based solutions can support Patient Registration, and various types of telehealth like Virtual Visits, Virtual Rounding, Virtual Interpretation (VRI), and Virtual Primary Care.
  • To assist in the response and readiness, Tryten is offering rapidly deployable, mobile, cost-effective carts, said Dr. Deborah Jeffries, Chief Strategy Officer at Tryten.
  • Click here to learn more about COVID Rapid Response Mobile Telehealth Carts , please visit us at www.tryten.com , contact us , or call 1.800.860.4455.

Agenus Corporate Update and Second Quarter 2021 Financial Report

Retrieved on: 
Monday, August 9, 2021

AGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021

Key Points: 
  • AGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021
    LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, todayprovided a corporate update and reported financial results for the second quarter of 2021.
  • Registrational trials targeted to commence by year-end 2021 with a focus on rapid path to Biologics License Application (BLA) submission.
  • We ended the second quarter of 2021 with a cash balance of $74 million as compared to $100 million at December 31, 2020.
  • Non-cash operating expenses for the second quarter ended June 30, 2021 were $30 million compared to $18 million for the second quarter of 2020.